NCS Multistage Surpasses Q4 Targets, Reports 42% Margin and ResMetrics Synergies
NCS Multistage topped Q4 2025 guidance, posting revenue, adjusted EBITDA and free cash flow above targets with a 42% gross margin. The ResMetrics acquisition strengthened international tracer diagnostics and is expected to yield cost savings and revenue synergies despite 2026 revenue being seasonally weighted to the back half.
1. Q4 2025 Outperformance
NCS Multistage exceeded the high end of its guidance range for revenue, adjusted EBITDA and free cash flow in Q4 2025, reflecting robust project execution across North America and international tracer diagnostic services.
2. Margin and Seasonality
Adjusted gross margin dipped to 42% from 43% year-over-year due to a higher mix of international diagnostic jobs, while management expects 2026 revenue to be skewed toward the back half because of seasonality and specific project timelines, particularly in the Middle East.
3. ResMetrics Acquisition Impact
The acquisition of ResMetrics bolstered the company’s global tracer diagnostic capabilities, driving anticipated cost savings and cross-selling opportunities in North America and laying groundwork for expansion into the Middle East and other international markets.
4. 2026 Guidance Outlook
Full-year 2026 guidance excludes potential disruptions from volatile trade or geopolitical conflicts; leadership is targeting new growth avenues in deeper North Sea operations, the Deepwater Gulf of America, high-temperature oil developments in Canada and enhanced geothermal systems.